Articles related to GLP-1s

Reductions in lean body mass are likely concentrated in non-contractile components rather than reflecting a clear decline in muscle function.

“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.” – Senior study author Ziyad Al-Aly, MD; Washington University School of Medicine

The approval was based on data from the randomized, double-blinded, parallel-group phase 3b STEP UP trial, which enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2, without diabetes.

“The increased risk of NAION with Wegovy is due to the higher dosage of semaglutide…the difference between the two dosages and the rates of NAION may indicate a dose-dependent increase in risk.” – Benjamin Bert, MD

“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors

The Wegovy tablet is the first oral GLP-1 receptor agonist indicated for weight loss and cardiovascular risk reduction in eligible adults.